Replies to post #122398 on Biotech Values

[mcbio]

Ponezumab (PF-04360365) and solanezumab (LY-206430) both were shown to raise CSF Abeta levels (including Abeta forms that are thought to only be present in brain plaques), which may be evidence of biological activity i.e. Abeta clearance from the brain.

Are you aware of any small-cap biotechs with drugs similar to ponezumab and/or solanezumab that have the potential benefit of raising CSF Abeta levels (either in the clinic or pre-clinical)? T.i.a.

[masterlongevity]

Its not clear whether raising or lowering CSF abeta is a good thing, and whether it is good or bad may be time dependent..
Some folks think it should temporarily be raised (as abeta is dissociating in the brain and funneling into CSF) until it is eventually lowered as more abeta is removed from the body.